Healthcare Industry News: Cook
News Release - May 15, 2006
Biopure Appoints Vice President of Medical AffairsCAMBRIDGE, Mass., May 15 (HSMN NewsFeed) -- Biopure Corporation (Nasdaq: BPUR ) announced today that A. Gerson Greenburg, M.D., Ph.D. has joined the company as vice president of Medical Affairs. A board-certified general surgeon and expert in oxygen therapeutics, Dr. Greenburg brings to Biopure over 40 years of experience in clinical care, quality systems, teaching and research. He will report to Biopure's CEO Zafiris G. Zafirelis.
A professor emeritus of surgery at Brown University School of Medicine in Providence, R.I., Dr. Greenburg retired from The Miriam Hospital in April 2006 after serving as chief of clinical quality management since 2003 and as surgeon-in-chief from 1986 to 2005. In 2005, he received the hospital's Charles C.J. Carpenter Outstanding Physician of the Year Award. He also led the effort to organize The Miriam's submission for the prestigious Malcolm Baldrige National Quality Award. Previously, he was chief of general surgery and surgical intensive care at the Veterans Administration Medical Center in San Diego, Calif., and was a professor of surgery at the University of California, San Diego. Earlier in his career, he served for two years as an active duty surgeon in the U.S. Air Force.
In the 1970's, Dr. Greenburg developed a method for preparing a solution of chemically modified hemoglobin for use as a red blood cell substitute. Since that time, his research interests have centered on the development of oxygen therapeutics. He is past president of the International Symposium on Blood Substitutes and a member of the International Society of Artificial Cells & Immobilization Biotechnology's Scientific Committee on Blood Substitutes.
Dr. Greenburg's many special appointments have included major positions at the National Board of Medical Examiners and consulting positions at the National Institutes of Health. He is a diplomate of the American Board of Surgery and a member of the American College of Surgeons and several other professional organizations. His bibliography includes over 250 publications, and he has served on the editorial board or as a reviewer for numerous medical and scientific journals.
Dr. Greenburg served his surgical residencies in Chicago, Ill. and completed a fellowship in trauma at Cook County Hospital. He earned his bachelor's degree and medical degree from the University of Chicago and his doctorate in industrial engineering/management sciences from Northwestern University.
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure® [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. This product has not been approved for sale in other countries. Biopure plans to apply in Europe, in mid 2006, for approval of an acute anemia indication in orthopedic surgery patients. The company is developing Hemopure for a potential indication in cardiovascular ischemia, in addition to supporting the U.S. Naval Medical Research Center's government-funded efforts to develop a potential out-of- hospital trauma indication. The company's veterinary product Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs.
Statements in this press release that are not strictly historical are forward-looking statements, including any that might imply that the Navy's proposed trauma trial will receive authorization to proceed or that Hemopure will receive marketing approval in Europe or the U.S. Actual results or their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, unexpected costs and expenses, delays and determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, and delays in or unpredictable outcomes of clinical trials. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Form 10-K filed on March 13, 2006, which can be accessed in the EDGAR database at the SEC Web site, http://www.sec.gov.
The content of this press release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.